Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

393 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
Eichhorst B, Niemann CU, Kater AP, Fürstenau M, von Tresckow J, Zhang C, Robrecht S, Gregor M, Juliusson G, Thornton P, Staber PB, Tadmor T, Lindström V, da Cunha-Bang C, Schneider C, Poulsen CB, Illmer T, Schöttker B, Nösslinger T, Janssens A, Christiansen I, Baumann M, Frederiksen H, van der Klift M, Jäger U, Leys MBL, Hoogendoorn M, Lotfi K, Hebart H, Gaska T, Koene H, Enggaard L, Goede J, Regelink JC, Widmer A, Simon F, De Silva N, Fink AM, Bahlo J, Fischer K, Wendtner CM, Kreuzer KA, Ritgen M, Brüggemann M, Tausch E, Levin MD, van Oers M, Geisler C, Stilgenbauer S, Hallek M; GCLLSG, the HOVON and Nordic CLL Study Groups, the SAKK, the Israeli CLL Association, and Cancer Trials Ireland. Eichhorst B, et al. Among authors: gregor m. N Engl J Med. 2023 May 11;388(19):1739-1754. doi: 10.1056/NEJMoa2213093. N Engl J Med. 2023. PMID: 37163621 Clinical Trial.
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.
Fürstenau M, Thus YJ, Robrecht S, Mellink CHM, van der Kevie-Kersemaekers AM, Dubois J, von Tresckow J, Patz M, Gregor M, Thornton P, Staber PB, Tadmor T, Levin MD, da Cunha-Bang C, Schneider C, Poulsen CB, Illmer T, Schöttker B, Janssens A, Christiansen I, Nösslinger T, Baumann M, Hebart H, Gaska T, Regelink JC, Dompeling EC, Lindström V, Juliusson G, Widmer A, Goede J, Goldschmidt N, Simon F, De Silva N, Fink AM, Fischer K, Wendtner CM, Ritgen M, Brüggemann M, Tausch E, Spaargaren M, Eldering E, Stilgenbauer S, Niemann CU, Hallek M, Eichhorst B, Kreuzer KA, Kater AP. Fürstenau M, et al. Among authors: gregor m. Blood. 2023 Aug 3;142(5):446-459. doi: 10.1182/blood.2023019634. Blood. 2023. PMID: 37172204 Free article. Clinical Trial.
R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial.
Chamuleau MED, Stenner F, Chitu DA, Novak U, Minnema MC, Geerts P, Stevens WBC, Zenz T, van Imhoff GW, Wu KL, Demandt AMP, Kersten MJ, Terpstra WE, Tick LW, Deeren D, Van Den Neste E, Gregor M, Veelken H, Böhmer LH, Caspar CB, Mutsaers P, Refos JM, Sewsaran R, Fu L, Seefat RL, Uyl-de Groot CA, Dirnhofer S, Van Den Brand M, de Jong D, Nijland M, Lugtenburg P. Chamuleau MED, et al. Among authors: gregor m. Lancet Haematol. 2023 Dec;10(12):e966-e975. doi: 10.1016/S2352-3026(23)00279-X. Epub 2023 Oct 31. Lancet Haematol. 2023. PMID: 37922925 Clinical Trial.
Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies.
Langerbeins P, Giza A, Robrecht S, Cramer P, von Tresckow J, Al-Sawaf O, Fink AM, Fürstenau M, Kutsch N, Simon F, Goede V, Hoechstetter M, Niemann CU, da Cunha-Bang C, Kater A, Dubois J, Gregor M, Staber PB, Tausch E, Schneider C, Stilgenbauer S, Eichhorst B, Fischer K, Hallek M. Langerbeins P, et al. Among authors: gregor m. Blood. 2024 Jun 20;143(25):2588-2598. doi: 10.1182/blood.2023022564. Blood. 2024. PMID: 38620092
ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia.
Eichhorst B, Ghia P, Niemann CU, Kater AP, Gregor M, Hallek M, Jerkeman M, Buske C; ESMO Guidelines Committee. Electronic address: [email protected]. Eichhorst B, et al. Among authors: gregor m. Ann Oncol. 2024 Sep;35(9):762-768. doi: 10.1016/j.annonc.2024.06.016. Epub 2024 Jul 3. Ann Oncol. 2024. PMID: 38969011 No abstract available.
Diagnostic challenges in complicated case of glioblastoma.
Aghova T, Lhotska H, Lizcova L, Svobodova K, Hodanova L, Janeckova K, Vucinic K, Gregor M, Konecna D, Kramar F, Soukup J, Netuka D, Zemanova Z. Aghova T, et al. Among authors: gregor m. Pathol Oncol Res. 2024 Oct 29;30:1611875. doi: 10.3389/pore.2024.1611875. eCollection 2024. Pathol Oncol Res. 2024. PMID: 39534304 Free PMC article.
Biodielectrics: old wine in a new bottle?
Barnana HD, Tofail SAM, Roy K, O'Mahony C, Hidaši Turiničová V, Gregor M, Ul Haq E. Barnana HD, et al. Among authors: gregor m. Front Bioeng Biotechnol. 2024 Oct 3;12:1458668. doi: 10.3389/fbioe.2024.1458668. eCollection 2024. Front Bioeng Biotechnol. 2024. PMID: 39420968 Free PMC article. Review.
Jag1 insufficiency alters liver fibrosis via T cell and hepatocyte differentiation defects.
Mašek J, Filipovic I, Van Hul N, Belicová L, Jiroušková M, Oliveira DV, Frontino AM, Hankeova S, He J, Turetti F, Iqbal A, Červenka I, Sarnová L, Verboven E, Brabec T, Björkström NK, Gregor M, Dobeš J, Andersson ER. Mašek J, et al. Among authors: gregor m. EMBO Mol Med. 2024 Nov;16(11):2946-2975. doi: 10.1038/s44321-024-00145-8. Epub 2024 Oct 2. EMBO Mol Med. 2024. PMID: 39358604 Free PMC article.
393 results